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Abstract (max 600 words) 
Context: Synthetic cannabinoids (SCs) such as “Spice”, “K2” etc. are widely available via the 
internet despite increasing legal restrictions. Currently, the prevalence of use is typically low in the 
general community (<1%) although it is higher among students and some niche groups subject to 
drug testing. Early evidence suggests that adverse outcomes associated with the use of SCs may be 
more prevalent and severe than those arising from cannabis consumption.    
Objectives: To identify systematically the scientific reports of adverse events associated with the 
consumption of SCs in the medical literature and poison center data. 
Method: We searched online databases (Medline, PsycInfo, Embase, Google Scholar and Pubmed) 
and manually searched reference lists up to December 2014. To be eligible for inclusion, data had to 
be from hospital, emergency department, drug rehabilitation services or poison centre records of 
adverse events involving SCs and included both self-reported and / or analytically confirmed 
consumption. 
Results: From 256 reports, we identified 106 eligible studies including 37 conference abstracts on 
about 4000 cases involving at least 26 deaths. Major complications include cardiovascular events 
(myocardial infarction, ischemic stroke, and emboli), acute kidney injury, generalized tonic-clonic 
seizures, psychiatric presentations (including first episode psychosis, paranoia, self-harm / suicide 
ideation) and hyperemesis. However, most presentations were not serious, typically involved young 
males with tachycardia (≈ 37-77%), agitation (≈ 16-41%) and nausea (≈ 13-94%) requiring only 
symptomatic care with a length of stay of less than 8 hours. 
Conclusions: SCs most frequently result in tachycardia, agitation, and nausea.  These symptoms 
typically resolve with symptomatic care, including intravenous fluids, benzodiazepines, and anti-
emetics, and may not require inpatient care.  Severe adverse events, (stroke, seizure, myocardial 
infarction, rhabdomyolysis, acute kidney injury, psychosis, and hyperemesis) and associated deaths 
manifest less commonly.  Precise estimates of their incidence are difficult to calculate due to the 
lack of widely available, rapid laboratory confirmation, the variety of SC compounds, and the 




unknown number of exposed individuals. Long-term consequences of SCs use are currently 
unknown. 
  





Synthetic cannabinoids (SCs) first appeared in the 1960s in research laboratories exploring potential 
medical uses targeting cannabinoid receptors. 1 At the end of the first decade of this century, SCs 
reappeared through internet marketing of so-called “legal highs”.   The best-known common names 
are “Spice” and “K2”. 1, 2 Although these products typically contain a variety of plant materials, 
most of the species reported are not believed to have psychoactive properties, with the primary 
active ingredients being synthetic cannabinoid (SC) receptor agonists sprayed onto the base 
material. 1 
 
The HU series (developed at the Hebrew University) the CP series (from Pfizer Inc.) and the JWH 
series (developed by JW Huffman) are the major groups of SCs. 3 These drugs can have a greater 
potency and binding affinity than Δ 9-tetrahydrocannabinol (Δ 9THC) the main intoxicant in 
traditional cannabis products that they mimic. 2, 3 Further, as potentially full agonists at the 
cannabinoid receptor (CB1), compared with the partial agonist properties of Δ 9THC, there is likely 
to be an increased risk of major psychiatric complications and other adverse effects. 1, 2 Other 
serious side effects, particularly sympathomimetic and hallucinogenic effects related to new 
compounds may be due to indirect activation of other receptors via excess activation of 
cannabinoids receptors, direct receptor activations due to mixed receptor effects of new 
cannabinoids, or possibly adulterants including plant material effects. 2 Winstock and colleagues 
estimated that the risk of requiring emergency medical treatment is between 14 and 30 times greater 
following the use of synthetic compared with traditional cannabis 4, with an online survey of SC 
users reporting that 2.5% had sought emergency treatment in the past 12 months. 5  
 
Data from population surveys suggest that recent use (i.e. last year) of ‘Spice’ like products is low, 
for example 0.2% in England and Wales 6 and 0.4% in Germany. 7 However, 2013 survey data from 
Australia suggests increasing rates of use with 1.2% of the population reporting use within one year 




and 2.5% in those under 25 years. 8 However, prevalence may be markedly higher in some sub-
populations. Heltsley et al, analysed urine samples from athletes who were subject to routine 
screening for performance enhancing and illicit drugs and found 4.5% were using synthetic 
cannabis, presumably assuming that, at the time, there was a low probability of detection. 9 A 
survey of 852 college students in Florida reported that 8% had ever used SC 10 and the American 
Monitoring the Future study reported an annual prevalence of 11.4% in 12th grade students (age 17-
18 years), second only to cannabis use. 11 Vandrey et al found that about 30% of SC users include 
the avoidance of drug testing among their reasons for using SCs, although though this figure may be 
higher in the United States due to the widespread testing of employees in some sectors (e.g. 
transportation, Federal agencies). 12, 13 
 
Data collection specific to emergency department (ED) presentations involving SCs began with the 
US National Forensic Laboratory Information System detecting 23 SC cases in 2009.  By 2012, this 
number had grown to over 41,000 cases. 14 Similarly, the US Drug Abuse Warning Network 
(DAWN) recorded over 11,000 cases in 2010 and over 28,000 in 2011. 15 Similar dramatic 
increases have also occurred in Europe. In the UK, there was a seven fold increase in enquires to 
TOXBASE between 2011/12 and 2012/13 by healthcare workers in relation to poisoning 
presentations involving SC. 16 Nevertheless, many emergency physicians are unfamiliar with SCs 
and feel unprepared to care for intoxicated users. 17  
 
The analysis of the chemical constituents of ‘Spice’ shows that the quantity and type of SCs varies 
widely, with some products containing no active compounds or other active non-cannabinoid 
substances such as the synthetic opioid O-desmethyltramadol. 18 Chronological analysis suggests 
that the SCs in commercial products may have changed in response to legislative restrictions: for 
example, JWH-073 appeared in Germany only after JWH-018 was controlled. 18 Thus, consumers 
are unlikely to be able to gauge the potential effects or risks of particular products as the 




constituents change over time. The method of preparation of these products further adds to the 
potential hazards associated with them. Production typically involves spraying chemical compounds 
dissolved in acetone onto a plant base. The resulting products may vary in the composition, 
concentration, and distribution of SCs within a batch and among batches of similar products. A 
further complication for medical staff assessing presentations thought to involve SCs is the lack of a 
simple urine or blood-screening test to confirm its presence. 19 
 
A recent paper on SCs adopted a comprehensive approach to examining the clinical implications 
arising from research into SCs, their epidemiology, receptor interactions, and human and animal 
pharmacodynamics. 20 The objective of this review is a more focused approach to identify the 
typical signs and symptoms of exposure to SCs and particular idiosyncratic presentations involving 
SCs from hospital presentations and poison centre data. We also aimed to summarize interventions 
or treatment provided in the hospital management of these cases when these data were available. 
Method 
In December 2014, we systematically searched Medline, PsycInfo, Embase, Google Scholar and 
Pubmed for reports. In brief the strategy was (emergency department OR hospital OR Poison 
Control Centers OR substance related disorders OR Drug Overdose) AND (Synthetic cannabis OR 
synthetic cannabinoid). Online data supplement 1 contains an example of the syntax (for the Ovid 
Medline search). Given the nascent state of the literature, we also backward searched the references 
of retrieved papers to identify early material such as conference presentations. 
Inclusion criteria 
The target substance was any SC (e.g. “Spice”, “K2” etc.). Adverse events had to be recorded by 
medical staff e.g. at hospitals, drug rehabilitation services, or emergency facilities as opposed to 
self-reporting via surveys. The exception to this were Poison Centre reports that collect data from a 
variety of sources, including the public, but are coded by specialists in poisons information, 




including nurses, pharmacists, or scientists. 21 Both self-reported and analytically confirmed use of 
SCs were eligible for inclusion, as were presentations involving SCs plus other drugs. 
Results 
We identified 323 records from the database search. We supplemented these with 41 from hand 
searching references (see Figure 1, PRISMA diagram).  After we had excluded duplicates and had 
screened titles, we reviewed 136 full texts: we subsequently excluded 30 (Online data 2). Overall, 
106 papers, letters and conference abstracts were eligible for inclusion in the study, representing 
over 4000 cases. The tables have been arbitrarily sub-divided into case series (defined as > 10 
cases) and case studies (<10 cases) on the expectation that the former will provide the more reliable 
evidence on the typical symptoms while the latter will have more detail on interventions and 
highlight the most unusual presentations. We identified 14 case series and 55 case reports from 
journals (Tables 1 and 2) plus a further 15 case series and 22 case reports from conference abstracts 
(online data 3). 
 
Poison Centre data, including nearly 1900 cases from the USA National Poison Data System for 
nine months in 2010, represented the largest samples. 22 The prototypical presentation is a young 
male (59-100%) with tachycardia (37-77%), agitation (16-41%) and nausea (13-94%) (see Table 1). 
Most cases received observation and supportive care (intravenous fluids, benzodiazepines, oxygen) 
and left emergency within eight hours. Nevertheless, some cases and series presented with more 
severe conditions. These cases typically do not include analytically confirmed exposure to SC. 
Mortality 
There have been both case series and case reports of deaths associated with the use of SC. Shanks 
and colleagues report on SC concentrations from samples collected during 18 autopsies, although 
the focus of the paper was primarily a methodological description of the analysis of JWH-018 and -
073 from post-mortem whole blood. 23 The same team reported on a further four deaths involving 
5F-PB-22, with sudden cardiac dysrhythmias or seizures suggested as a potential mechanism in 




three of the cases, whilst, in the fourth, liver and kidney failure was noted. 24 Deaths have been both 
attributed directly to synthetic cannabinoid use 22, 25-27 (JWH-018, -081, -122, -210, -250: 
MAM2201: JWH-018 UR-144 N- (5-hydroxypentyl), UR-144 N-pentanoic acid) and in other 
instances the use appears to have indirectly caused fatalities with deaths attributed to hypothermia 
(unconscious outdoors in winter) 28 (JWH-210), jumping from a building 29 (SC type unknown) or 
suicide / self-injury 23, 30 (JWH-018 83.3 ng/ml: AM2201). The two studies by Shanks et al 23, 24 
may include deaths reported in other USA case studies. Thus, a conservative estimate of the number 
of reported SC deaths is 22 (maximum 27) in the USA, three from Europe and one in Japan. 
Cardiovascular 
Tachycardia is the most prevalent clinical effect reported in the literature. Poison Centres frequently 
record this effect in association with hypertension as symptoms of SC presentations, with 
tachycardia occurring in 1/3 to 3/4 of presentations. 31-33 In some cases, there are also reports of 
chest pain. 34-36 In addition, there are case reports of more severe outcomes including peri-
mesencephalic subarachnoid haemorrhage 37, middle cerebral artery occlusion 38-41 and three cases 
of myocardial infarction in adolescent males. 42 Ibrahim and colleagues also report a cardiac arrest 
in a 56 year-old man with an earlier four-vessel bypass graft. 43 
Acute kidney injury (AKI) 
Poison Centre data show that queries on renal problems account for less than 1% of SC calls 44 but 
various reports describe acute kidney injury (AKI) in the setting of acute SC toxicity. The Centers 
for Disease Control (CDC) identified 16 AKI cases over nine months, typically presenting as 
nausea, vomiting and flank pain with associated elevated peak serum creatinine (range 3.3-21.0 
mg/dl). SCs exposure was analytically confirmed in six of seven cases tested (XLR-11, UR-144, 
indole precursor). There was also evidence of elevated white blood cell count, proteinuria and 
haematuria. Renal biopsies in a series of eight patients found acute tubular injury (five patients), 
acute interstitial nephritis (two patients) or both (one person). 45 An additional four AKI cases were 




reported from Alabama in otherwise healthy young men 46 and nine in Oregon (including five 
previously recorded by the CDC). 45 All required hospitalization for up to eight days. 47 
Generalized tonic-clonic seizure (GTC) 
The Hoyte review found 52 (3.8%) poison centre reports on SCs included GTC seizures with two 
cases of status epilepticus (SC unknown). 22 However, in a CDC case series of emergency 
department SC presentations, 14% involved GTC seizures 48 and a review of paediatric (0-19 years) 
poison centre reports found that 15% involved seizures. 49 Seizures are also prominent in the case 
report literature, including those with analytically confirmed SC exposure (e.g. JWH-122, -210, -
018: PB-22: BB-22, AM-2233, PB-22, 5F-PB-22, JWH-122). 50-55 
Gastrointestinal 
Nausea and vomiting are often conspicuous features of SC presentations (e.g. Table 1 nausea or 
vomiting reported in 13-94% of presentations). Two papers report on cannabinoid hyperemesis 
subsequent to the use of SC.56, 57 Both case reports outline a characteristic cycle of nausea, vomiting 
and abdominal pain relieved by hot showers similar to the hyperemesis syndromes seen with 
cannabis abuse. Hopkins and colleagues analytically confirmed SC use, with no cannabis detected 
in a urine screen. 56 
Psychiatric presentations 
As noted in the Tables 1 and 2, many presentations include behavioural features such as agitation. 
However, more severe psychiatric presentations are also prevalent. Hurst et al reported on 10 cases 
of new onset psychosis associated with SC use from San Diego, although only two involved just the 
use of SCs, with the remainder consuming cannabis or alcohol either concurrently or in the recent 
past. 58 Hospitalization lasted between 6-10 days and in one case, symptoms persisted for more than 
five months. An audit of an open adult ward in New Zealand found 13% (n=17) of psychiatric 
admissions were probably related to SC consumption, including four first time admissions 
(affective, suicidal or psychotic symptoms) plus four first admissions with psychosis. 59 New onset 
psychosis has also been reported by others 60-64 including with significant self-injury 65, catatonic 




features 66 and Capgras delusion. 67 SC use has also been described as exacerbating symptoms in 
those receiving psychiatric treatment 68, initiating drug induced psychosis (with no known history of 
drug-induced psychosis), 69 and precipitating a recurrence of cannabis induced psychosis. 70  
 
SC presentations also include symptoms of panic attack 51, 71, anxiety, paranoia and hallucinations. 
72, 73 Two case reports have described withdrawal symptoms following the cessation of SCs 74, 75 
similar to those associated with cannabis withdrawal. 76  
 
Discussion 
The prevalence of synthetic cannabinoid (SC) consumption is low in the general population. 6-8 
However,  the risk of requiring medical attention following use of SC seems to be greater than that 
for cannabis consumption. 4 Our systematic review of adverse events found that typically events 
were not severe, only required symptomatic or supportive care and were of short duration. 
Nevertheless, a number of deaths have been attributed either directly or indirectly to SC 
consumption, together with other major adverse sequelae, including a significant number with 
persistent effects including new on-set psychosis with no family history of psychosis. 58 
 
We did not include popular media reports or the grey literature in the search, which would probably 
reveal further cases but would be less likely to contain reliable medical information. We were 
unable to determine the exact number of cases in the scientific literature due to the potential overlap 
between poison centre data and hospital reports. We could not even definitively established the 
number of deaths attributed to SC consumption. Of the 28,531 ED visits in 2011 recorded in the 
DAWN database, 119 (0.4%) led to death potentially related to SC use. 77 Our review of published 
cases identified only 22 fatal cases in the US through the end of 2014. As not all presentations 
especially for psychiatric problems or palpitations will include assessment of SC use, SC 
presentations may currently be seriously underreported. This suggests that the magnitude of the 




health burden due to SC use is considerably greater than that currently documented. Most of the 
data were based on self-reported consumption of SC, with no simple screening test available yet for 
clinicians.  
 
Some of the information on adverse effects of SCs arises from poison center data.  Wood et al 
outlined the strengths and weakness of poison center data for novel psychoactive substances. 21 In 
brief, poison centers may detect new and unfamiliar exposures, but the rates of detection may 
decline with familiarity with the substances involved.  In addition, the data depend upon voluntary 
reporting, often lack analytical confirmation, and may not discern which symptoms to attribute to a 
given substance, in cases of poly-drug exposure. Similarly, novel adverse events and events 
involving new SCs are more likely to be reported or published in the medical literature. 
 
The consumption of cannabis affects the cardiovascular system and increases the risk of myocardial 
infarction. 78, 79 Similarly, cannabis has been implicated in ischemic stroke, especially multifocal 
intracranial stenosis among young adults. 80 The potential mechanisms include cardiac ischemia due 
to increased heart rate, postural hypotension, impaired oxygen supply arising from raised 
carboxyhemoglobin levels, especially in conjunction with tobacco smoking, and catecholamine-
mediated pro-arrhythmic effects. 81 It is thus perhaps unsurprising that similar adverse outcomes 
have occurred following the use of SCs given their increased potency at CB1 receptors. Whether 
these compounds have significant direct effects on other receptors is still unknown. 
 
The comparatively short period for which SC have been available and used in the general 
community means that long-term outcomes are currently unknown. However, the occurrence of 
acute kidney injury has implications for future health with a meta-analysis estimating a nearly nine-
fold increase in the risk of developing chronic kidney disease, and a three-fold increase in the risk 
for end stage renal disease, compared to those who have not had AKI. 82 Thus, even low prevalence 




events with apparently limited duration, like AKI, have the potential to result in significant health 
costs following the resolution of acute symptoms. The other effects with long-term potential health 
consequences are initiation or exacerbation of psychiatric disorders, particularly psychosis. These 
are extremely debilitating and disabling conditions with large societal and health impacts for 
patients, families and the health system. 
Clinical Implications 
Synthetic cannabinoid intoxication appears to be a distinct and novel clinical entity. Use of SCs can 
cause more significant clinical effects than marijuana. There also appear to be qualitative 
differences in the nature of the symptoms with which patients present. The sheer number of SCs 
available and the rate at which they continue to change confound examinations of the scale and 
extent of the problem. 83 More recent formulations (in the UK termed ‘Third Generation’) are 
typically more potent that earlier SCs and seem to be associated with greater harms. 84 Trecki and 
colleagues report that the incidence of clusters and severity of adverse events involving SCs appears 
to be increasing. 85 This increase could be due to greater familiarity with presentations, better 
coordination between public health authorities and laboratories or the characteristics of newer SCs. 
85 
 
The overall effects of SC can resemble those of cannabis, but other than anxiety and paranoia these 
are not usually the symptoms associated with acute hospital presentation. Instead, patients seem to 
present in EDs because of behavioural abnormalities (agitated behaviour, psychosis, anxiety) or 
symptoms associated with acute critical illness. The latter includes seizures (which if prolonged can 
lead to rhabdomyolysis and hyperthermia), AKI, myocardial ischaemia and infarction in 
demographic groups where this would be most unusual. The majority of mild intoxications only 
require symptomatic treatment and generally do not require hospital admission. Severe 
intoxications, involving seizures, severe agitation or mental health disturbances, arrhythmias and 
significant chest pain, should be admitted to hospital for further investigation.  





The lack of an antidote to SCs, analogous to that for opioid overdose, complicates management, as 
does the unpredictable effects and lack of a clear toxidrome to distinguish SCs from other 
recreational drugs. 85 The differential diagnosis requires the elimination of diverse conditions 
including hypoglycemia, CNS infection, thyroid hyperactivity, head trauma and mental illness. 86 
Benzodiazepines are usually sufficient to control agitation: while the use of haloperidol has also 
been described, 86 caution is advised in undifferentiated agitation. Benzodiazepine failure should 
prompt consideration of definitive airway control. In addition to intravenous fluids for dehydration, 
the primary goals are protecting the airway, preventing rhabdomyolysis and to monitor for either 
cardiac or cerebral ischemia. 86 
 
Traditionally, most recreational drug overdoses have been easily explicable based on clinical 
presentation alone. From an epidemiological perspective, this position should be revisited. Both the 
Welsh Emerging Drugs and Identification of Novel Substances (WEDINOS) and the Australian 
Capital Territory Novel Substances (ACTINOS) projects, routinely analyse raw product samples in 
the possession of patients, associated with severe or unusual presentations. This protocol has been 
able to characterize novel products well before their identification by law enforcement, arguably 




Data from poison centers and drug monitoring systems in Europe, the UK, the US, and Australia 
illustrate trends of increased use of SCs.  The number of unique SCs appears to continue growing, 
but the SCs seem to share common characteristics within the class.  The most common effects 
include tachycardia, agitation, and nausea; these generally respond to supportive care.  However, 




physicians should be aware of the severe cardiovascular, cerebrovascular, neurological, psychiatric, 
and renal effects, which occur in a minority of cases.   
 
Differences among compounds in the class are difficult to assess.  Methods to detect, identify, and 
confirm new SCs lag behind the appearance of these drugs.  Further, many of the cases depend 
upon self-report of the patients, whose information may be unreliable or inaccurate.  Improving the 
availability of advanced laboratory resources will improve our ability to recognize SCs with higher 
risk of severe toxicity.  
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n: sex, age 
Effects Signs & symptoms Analysis / compounds Treatment / length of stay 
Castellanos  
87/ USA 
11: 91% ♂, 
mean 17 years 
Euphoria, memory changes, 
auditory / visual changes 
(Adolescent Addiction Centre) 
Paranoid thoughts 35%, palpitations 
27%,  
Self-report / SC (plus alcohol and 
cannabis) 
NR / NR 
CDC 88 / 
USA 
127: 80% ♂, 
median age 26 
Lethargy 35%; aggression 32%, 
agitation 32% 
Systolic BP >120 64%, HR >100 
57% 
Self-report / various brands of SC NR / NR (87% discharged from 
ED: 13% admitted, 8% to ICU) 
CDC 48 / 
USA 
22: 82% ♂, 
median age 25  
Nausea/vomiting 36%, aggression 
32%, confusion 32%, lethargy 
32%: seizures 14%,   
Hyperglycaemia 59%, tachycardia 
59%, hypokalaemia 41%, acidosis 
32%, pneumonia n=2, MI n=1, 
rhabdomyolysis n=1 




NR / NR (27% to ICU) 
CDC 45 / 
USA 
16: 94% ♂, 
median age 
18.5 
Nausea & vomiting 94%, 
abdominal, flank ± back pain 75% 
Creatinine peak 3.3 – 21.0 mg/dL Self-report + 7  lab report / XLR-
11, UR-144, indole precursor 
Haemodialysis 31%, 
corticosteroids 26% / NR all 
admitted to hospital. 
Forrester a 
31, 44 / USA 
464: 74% ♂, 
mean age 23 
Agitation 19%, lethargy 19%, 
vomiting 16%, hallucinations 
11% 
Tachycardia 37%, Self-report including any SC IV fluids 39%, BZD 19%, oxygen 
8% / NR 
Forrester a b 
89 / USA 
305: 72% ♂, 
mean age 16.7 
Lethargy 24%, agitation 16%, 
vomiting 13%, hallucinations 
12%: death n=1 
Tachycardia 42%, hypertension 8%,  Self-report including any SC NR / NR 
Glue 59 / 
New 
Zealand 
17: 59% ♂, 
mean age 26 
Psychiatric admissions Psychoses 59%, affective 82%, 
suicidal ideation 82%, homicidal 
6% 
Self-report / “K2” Antidepressants, anti-psychotics / 
Mean 8.5 days 
Helander 32 / 
Sweden 
22: 78% ♂, 
mean age 20 
Emergency department 
admissions 
Tachycardia 77%, mydriasis 73%, 
somnolence 36%, tremor 27%, 
agitation 23%, hypotension 23% 
emesis 23%  
LC-T-MS / JWH-015, -018, -019, -
021, -081, -210, -250 
NR / NR 
Hermanns-
Clausen a 33 
29: 86% ♂, 
median age 19 
Agitation 41%, hallucinations 
38%, nausea / vomiting 28%, 
vertigo 24%, panic 21%, 
Tachycardia 76%, hypertension 
34%, mydriasis 38%, hypokalaemia 
(< 3.1 mmol/L) 28%, BGC (<200 
LC-ESI-T-MS & GC-MS / JWH -
015, -018, -073, -081, -122, -210, -
250, AM-694, CP-47, 497-C8, Δ9-
BZD 31%, potassium 17%, IV 
fluids 17%, anti-emetic 7%, 
Intubation n=1, haloperidol n=1, 




/ Germany dyspnoea 21%, lethargy 17% mg/dL) 31% THC neuroleptic n=1 / NR median 
symptom duration 7.5 hours) 
Hoyte a 22 / 
USA 
1898: 73% ♂, 
mean age 22.5 
Agitation 23%, vomiting 15%,  
lethargy 14%, confusion 12%, 
seizure <4%, status epilepticus 
n=2, death n=1 
Tachycardia 40%, hypertension 8%, Self-report of single agent exposure 
/ (various brands of SC) 
IV fluid 25%, BZD 16%, oxygen 
6%, anti-emetics 5% / NR 
(Clinical effects: < 8 hours 75%, 
8-24 hours 17%, >24 hours 5% 
Hurst 58 / 
USA 
10: 100% ♂, 
age range 21-
25 
New onset psychosis Paranoid delusions 90%, odd/flat 
affect 60%, hallucinations 60% 
Self-report / various brands of SC 70% anti-psychotic medications / 
inpatients 6-10 days (symptoms 
70% < 8 days, 30% > 5 months) 
Monte a 90 / 
USA 
76:72% ♂, 
median age 28 
Altered mental state 68%, 
agitation 42%, seizures 14% 
HR median 100, bradycardia 
developed (median HR 63, time 179 
minutes) 
MS / ADB-PINACA (N-[1-amino-
3,3-dimethy-1-oxobutan-2-yl]-1-
pentyl-1Hindazole-3-carboxamide) 
BZD 42%, antipsychotics 14%, 
ketamine 3% intubation 13% / 
NR 
Shanks 23 / 
USA 
18: sex & age 
not reported 
Autopsies (blood analysis)  LC- ESI-T-MS / JWH-018, -073 
Concentration JWH-0180.5 ng/ml 
– 199 ng/ml 
NA / NA 
 
BGC = blood glucose concentration: BP = blood pressure: BZD = benzodiazepines:  GC-MS Gas chromatography mass spectrometry: IV intravenous: K = Potassium: LC-ESI-T-MS 
= Liquid chromatography-electrospray ionization-tandem mass spectrometry: LC-T-MS = liquid chromatography-tandem mass spectrometry: MS = mass spectrometry: NA = Not 
applicable: NR = not reported: RR = respiration rate: SC = synthetic cannabinoids:  
a Poison Centre data are received from various sources but are evaluated by the poison centre staff who are trained nurses, pharmacists, or physicians.  
b Note: analysis of events in those aged <20 (305 cases, 74% ♂ mean age 16.7) 180 in earlier paper 31 with adult cases  
c Also reports on police samples from suspects - not eligible for review – no ED data 
  








n: sex, age 
Effects Signs & symptoms Analysis / compounds Treatment / length of stay 
Alhadi 91 / 
USA 
1: ♂, age 21 Chronic cough, diverse 
pulmonary infiltrates, severely 
hypoxemic 
HR 118, BP 182/108, RR 42 LC-T-MS/ AM-2201, JWH-122, -
210, -018 
Mechanical ventilation, 
antibiotics, steroids / > 8 days 
Bebarta 92 / 
USA 
1: ♂, age 25 GTC seizure, vomiting HR 107, BP 114/69, RR 14, WBC 
16 k/µL 
Self-report “Spice” Diazepam 10mg IM / > 1day 
Bebarta 72 / 
USA 
a) 1: ♀, age 19 
b) 1: ♂, age 19  
c) 1: ♂, age 23 
a) lethargy, amnestic, agitated  
b) paranoia, aggression, 
hallucinations  
c) panic, agitation difficulty 
breathing 
a) BP 138/70, WBC 17 k/µL, BGC 
220 mg/dL 
b) HR 114, BP 146/78, BGC 197 
mg/dL 
c) HR 110, RR 28, WBC 13 k/µL 
Urine TLC + GC-MS – no illicit 




a) lorazepam 2mg IV / 1 day 
b) naloxone, observation / 1 day 
c) lorazepam, IV fluids, 




a) 1: ♂, age 17 
b) 1: ♂, age 27  
c) 1: ♂, age 18 
 
d) 1: ♂, age 19 
a) dead on arrival 
b) died post admission  
c) dead on arrival 
 
d) dead on arrival 
b) severe liver & kidney injury, 
respiratory failure 
c) bilateral pulmonary vaso-
congestion 
d) bilateral pulmonary oedema 
All LC-ESI-T-MS 
a) / 5F-BP-22 1.1 ng / ml 
b) / 5F-BP-22 1.3 ng/ml 
c) / 5F-BP-22 1.5 ng/ml 
d) / 5F-BP-22 1.5 ng/ml 
a) intoxication: accidental 
b) fulminant liver failure: 
undetermined 
c) acute intoxication accidental  
d) acute intoxication: accidental 
Benford 60 / 
USA 
1: ♂, age 20 Anxiety & paranoia (new onset 
psychosis?), hallucinations, 
diaphoretic 
Tachycardia Self-report “Spice” NR / NR 
Bernson-
Leung 38 / 
USA 
a) 1: ♀, age 22 
b) 1: ♀, age 19 
a) drowsiness, inattention, 
dysarthria, hemibody weakness,  
b) left facial weakness, left-sided 
numbness, and dysfluency 
a) dysarthria, left hemiplegia, left 
hemi-anesthesia: MRI cerebral 
artery acute ischemic stroke 
b) aphasia left facial droop, left 
hemi-anesthesia: MRI cerebral 
artery infarction 
a) Self-report / ”K2” 
b) Self-report “Peak extreme” 
a) aspirin / NR 
b) warfarin / NR 
Berry-
Caban 69 / 
USA 
1: ♂, age 20 Uncommunicative, agitated – 
drug induced psychosis 
Tachycardia 160 Self-report SC Lorazepam 2mg, 25 mg 
diphenhydramine, 1mg 
risperidone / 9 days 
Bhanushali 
46 /USA 
4: ♂, age 20-
30 years 
Emesis, abdominal pain Peak creatine 3.2 - 15.2 mg/dL, 
haemoglobin 12.0- 16.8 g/dL, WBC 
8.1- 12.4 k/µL: 3 kidney biopsies – 
Self-report  “Spice” No renal replacement therapy 
required / NR 




acute tubular necrosis 
Buser 47 / 
USA 
9: ♂, median 
age 18 
Intense nausea, flank pain (acute 
kidney injury) 
Systolic BP 138-172, Peak 
creatinine median 6.6 ng/mL 
Self-report SC + LC-TOFMS / 
XLR-11 
Anti-hypertensives, steroids, 
dialysis (n=1) / 2-8 days 
Cohen 93 / 
USA 
3: 2 ♂, mean 
age 16.6 
a) Catatonic,  
b) agitated & aggressive,  
c)’frozen’ face, agitated 
a) HR 105, BP 118/73, RR 18:  
b) HR 131, BP 131/89, RR 24:  
c) HR 62, BP 110/52, RR 12 
Self-report /  
a) “K2”,  
b) “Spice” 
c) “Spice”  
a) Diphenhydramine 50mg IV, 
lorazepam 2mg IV x2 / 1 day 
b) Diphenhydramine 50mg IV, 
lorazepam 2mg IV / <1 day 
c) Normal saline 1000mL, 
lorazepam 4mg IV / <1 day 
de Havenon 
94 / USA 
a) 1: ♂, age 24  
b) 1: ♀, age 36 
a) GTC seizure  
b) GTC seizure: status epilepticus 
a) supratentorial sulcal CSF: EEG 
mildly encephalopathic 
 b) EEG mildly encephalopathic 
WBC 12.4 k/µL. 
Self-report / “Spice” a) NR/ NR 
b) intubated, lorazepam, 
etomidate, vecuronium, propofol, 
evetiracetam, phenytoin / NR 
Derungs 95 / 1: ♂, age 31 Agitation, anxiety, aggression, 
vomiting, transient psychotic state 
HR 144, BP 160/100 GCS 13 
hypokalaemia 3.2 mmol/L 
GC-MS / MAM-2201 Observation / 3 hours 
Every-
Palmer 68 / 
New 
Zealand 
5: (age / sex 
not reported) 
Florid psychosis Existing forensic inpatients NR / CP47, 497, JWH-018 NR / NR 
Faircloth 96 / 
USA 
1: ♂, age 17 Emesis, confusion, lethargy HR 132, BP 158/86, RR 30, GCS 9, 
BGC 121 mg/dL, hypokalaemia (3.2 
mmol/L) 
Self-report / SC “K2” Normal saline, oxygen / NR 
Gugelmann 
50 / USA 
1: ♂, age 22 GTC seizure HR 106, BP 167/102, RR 24, GCS 3 LC-QTOFMS / synthetic 
cannabinoid PB-22 
Ondansetron 4mg IM, midazolam 
5mg IM, intubation, midazolam 
4mg, etomidate, rocuronium. 
propofol IV / NR 
Harris 34 / 
USA 
6: 83% ♂, age 
17-24 
Agitation, seizures,  high risk 
behaviours, hallucinations, 
inability to move limbs, emesis, 
syncope, chest pain 
Tachycardia (83%) hyperreflexia 
(50%) 
Self-report / SC Observation / 1-4 days 
Health 35/ 
USA 
a) 1: ♂, age 17 
b) 1: ♂, age 15 
a) stuporous & confused 
b) unconscious 
HR 180, chest and back pain, other 
tests normal ranges 
b) HR 172, BP 162/57, RR 16 
Both self-report / SC a) adenosine 6 mg IV / 1 day 
b) IV fluids / 1 day 
Hermanns-
Clausen 51 / 
4: ♂, mean 
age 18.25 
a) GTC Seizure, emesis 
b) lethargy  
a) (HR & BP ‘normal’), BGC 128 
mg/dL, WBC 14.2 k/µL 
LC-ESI-T-MS / a) JWH-122, -210, 
-018 BZD, cannabinoids 
a) intubated, midazolam IV, 
bronchoscopy for aspiration  / 3 




Germany c) agitation, trembling, panic, 
emesis 
d) emesis, unable to communicate 
b) HR 160, WBC 11.3 k/µL,  
c) HR 112, hypokalaemia 
(2.9mmol/L) BGC 161 mg/dL,  
d) HR 100, WBC 15.4 k/µL, 
hypokalaemia (3.0 U/L) 
b) MAM-2201, UR-144, JWH-122, 
metabolite JWH-018  
c) JWH-081, metabolite JWH-073  
d) JWH-122 metabolite JWH-018 
BZD 
days 
b) NR / <1 day 
c) IV fluids, potassium  / < 1day 
d) IV fluids, potassium, BZD  / 
1day 
Hopkins 56 / 
USA 
1: ♂, age 30 Intractable abdominal pain, 
nausea & emesis (relieved by hot 
showers) 
Diagnosis: cannabinoid hyperemesis GC-LC -MS / JWH-018, -073, -
122, AM-2201, -694 
IV fluids, Ondansetron IV, 
promethazine suppositories / NR 
Ibrahim 43 / 
USA 
1: ♂, age 56 Cardiac arrest, ventricular 
fibrillation, comatose 
Sinus tachycardia, GCS 3, troponin 
T 0.632, CKMB 70.2 index 8.6% 
Self-report  “K2” Defibrillated x2 (epinephrine, 
atropine, lidocaine IV), induced 
hypothermia / NR 
Jinwala 97 / 
USA 
a) 1: ♂, age 19 
b) 1: ♂, age 15 
a) seizure, altered mental state 
b) difficulty breathing 
a) HR 68, BP 110/65, RR 7 
b) RR 8 
Self-report “K2” 
Self-report “Silver K2” 
a) intubated / NR 
b) endotracheal intubation 2 days 
/ 4 days 
Johnson 61 / 
USA 
1: ♂, age 23 Paranoid delusions (no history 
mental illness) 
No abnormal readings (e.g. blood, 
metabolic, thyroid screens) 
Self-report “Spice” NR / NR (symptoms resolved in 
24 hours). 
Kamat 37/  
New 
Zealand 
1: ♂, age 17 Severe global headache, emesis, 
visual disturbance 
CT scan perimesencephalic 
subarachnoid haemorrhage & 
aneurysm 
Self-report  “Kronic Purple Haze” MicroPlex 10 coil inserted / 22 
days 
Krostrand 28 
/ Sweden c 
1: ♂, age 17 Dead on arrival: hypothermia + 
intoxication 
(Intoxicated outdoors at night) LC-T-MS / JWH-210 NA / NA 
Lapoint 52 / 
USA 
1: ♂, age 48 Generalized seizure Sinus tachycardia HR 106: BP 
140/88 RR 22  
GC-MS & LC-T-MS / JHW-018 lorazepam IV, intubated, electric 
cardioversion / >3 days 
McQuade 53 
/ UK 
1: ♂, age 20 GTC seizure (history of poor 
diabetes management) 
GCS 14, HR 93, BP 152/63 LC-MS / AM-2201 / self-report 
“Black mamba” 
Normal saline  / 2 hours DAMA 
Meijer 65 / 
USA 
1: ♂, age 26 (Paranoia) self-inflicted 4th degree 
burns hands & arms: overall 
14.5% body area  
(Bilateral amputation) Self-report / SC “Black Diamond” Extensive surgery including 
amputations of fingers on both 
hands, multiple skin grafts / NR 
Mir 42 / 
USA 
3: ♂, mean 
age 16 
a) 3 days chest pain,  
b) 1 week chest pain  
c) 3 day chest pain 
a) troponin 3 ng/mL ↑25 ng/mL:  
b) troponin 11.6 ng/mL  
c) troponin 7 ng/mL ↑12 ng/mL 
Self-report / “K2” a) NR / > 2 days 
b) NR / NR 
c) NR / NR 
Müller 70 / 
Germany 
1: ♂, age 25 (Recurrent) psychotic episode, 
paranoid hallucination, imperative 
voices 
- Self-report / “Spice” NR / NR 




Müller 71 / 
Germany 
1: ♂, age 21 Panic attack, blurred vision, 
unsteady gait, palpitations, 
sweating (History of ADHD) 
Tachycardia Self-report / “Spice” IV fluids, lorazepam 2mg IV / > 1 
day 
Nacca 36 / 
USA 
1: ♀, age 22 
 
1: ♂, age 20 
a) Cramp, pain, chills, cravings, 
anxiety (withdrawal) 
b) Chest pain, palpitations, 
dyspnoea, headache (withdrawal)  
a) HR 100, BP 110/78, RR 28, mild 
leucocytosis & acidosis 
b) HR 120, BP 106/58, RR 18, CPK 
753 IU/L 
a) Self-report / SC 
 
b) Self-report / SC 
a) 2 L IV fluid, 2 mg IV 
lorazepam / 3 hours 
b) BZD, hydroxyzine, 
diphenhydramine, quetiapine 50 
mg 
Oluwabusi 
62 / USA 
a) 1: ♂, age 19 
b) 1: ♂, age 17 
a) new onset psychosis 
b) new onset psychosis 
(both cases had subsequent re-
admissions following SC use) 
a) self-report / SC 
b) self-report / SC 
a) quetiapine, aripiprazole 
b) olanzapine 
Pant 98 / 
USA 
1: ♂, age 48 GTC seizures HR 106, BP 140/88, RR 22, GCS 
10, creatine phosphokinase 1200 
U/L 
LC-T-MS / JWH-018 no other 
illicit drugs, alcohol 140 mg/dL 
4mg lorazepam / NR 
Papanti 99 / 
Italy 
1: ♂, age 18 Confused and agitated Tachycardia, HR 180, BP 137/90, 
RR 18 
Self-report / “Bonzi” Olanzapine 5 mg, bromazepine 
3mg / NR (symptoms 4 weeks) 
Patton 30 / 
USA 
1: ♂, age 23 Dead on arrival – (self-inflicted) 
stab wound 
Blunt trauma to hands, sharp force 
wounds head & upper extremities 
LC-MS-MS / AM2201 NA / NA 
Peglow 63 / 
USA 
1: ♂, age 59 Psychotic symptoms (history of 
poly substance abuse 3 years 
prior) 
- Self-report / “Spice” NR (return to outpatient 
medications) / 1 day 
Quan 100 / 
USA 
1: ♂, age 20 Anxiety & confusion  Sinus tachycardia, HR 114, BP 
148/89, mild leukocytosis & 
elevated blood urea nitrogen 
/creatinine ratio  
Self-report / “Spice” IV fluids, Ondansetron 4 mg IV/ 
2 hours 
Rahmani 64 a) 1: ♂, age 17  
a) 1: ♂, age 17 
a) Psychotic symptoms, agitation, 
b) Psychotic symptoms 
 
a) Delusions, hallucinations 
b) Agitated (required 4 point 
restraint). Hallucinations, disordered 
thoughts 
a) Self-report / “Spice” (LSD, 
psilocybin, mushrooms, ‘bath 
salts’, oxycodone) 
b) self-report / “Spice” (cannabis, 
LSD, ecstasy, BZD) 
a) Risperidone, clozapine, 
lorazepam, haloperidol, valproic 
acid, chlorpromazine, metoprolol 
/ 120 days 
b) Risperidone, clozapine, Haldol, 
lorazepam, valproic acid / 25 days 
Saito 25 / 
Japan 
1: ♂, age 59 Dead on arrival Autopsy – no evidence violence / 
disease 
LC-ESI-T-MS / MAM2201 NA / NA 
Schep 54 / 
New 
Zealand 
1: ♂, age 23 Seizure, emesis, discharged, 
seizure, CT brain scan normal 
K 3.3 mmol/L, lactate 5.2 mmol/L, 
creatinine kinase 338 U/L, WBC 
18.9k/ µL 
LC-MS / BB-22, AM-2233, PB-22, 
5F-PB-22, JWH-122 
IV fluids, oral diazepam / <1day 




Schneir 55 / 
USA 
1: ♂, age 19 Generalized seizure, vomiting HR 84, BP 177/83, RR 18 Lab test / JWH-018, -081, -250, 
AM-2201 (Urine screen BZD) 
Midazolam 5mg intranasal/ NR 
Schneir 73 / 
USA 
a) 1: ♀, age 22 
b) 1: ♀, age 20 
 
Anxiety, palpitations 
Anxiety, “feeling psychotic” 
a) Chemistry & bloods normal 
b) HR 126 (refused further tests) 
a) GC-MS / JWH-018, -073 a) Observation / 1 hour 




a) 1: ♂, age 21 
  
b) 1: ♂, age 27  
c) 1: ♂, age 21 
a) emesis & seizure 
 
b) emesis, confusion, agitation 
c) emesis & agitation 
a) sinus tachycardia & tachypneic, 
WBC 14 k/µL  
b) WBC 14 k/µL, BGC 186 mg/dL 
c) Mild tachycardia, WBC 19 k/µL 
hypokalaemia (3.3 mmol/L) 
All self-report / “Spice” a) 2 L saline, diphenhydramine 
25mg IV / 1day 
b) 2 L saline / 1day 




a) 1: ♂, age 25 
  
b) 1: ♂, age 21 
  
c) 1: ♂, age 19 
a) possible seizure, non-verbal / 
non-responsive,  
b) unresponsive, possible seizure, 
agitated,  
c) paranoia & delusions 
a) HR 122, BP 109/47, lactate 5.7 
mmol/L, pH 7.24, PCO2 63 mmHg  
b) GCS 7, HR 48, BP 204/103, RR 
8, WBC 16k/µL, BGC 198 mg/dL, 
lactate 3.3 mmol/L, creatinine 
kinase 867 U/L  
c) HR 85, BP 149/67, RR 16 
LC-T-MS /  a) JWH-018, 
 
b) metabolites of JWH-018, -073,  
 
c) metabolites of JWH-018, -073 
a) IV fluids, lorazepam 4mg IV / 
3 hours 
b) bag valve mask / NR 
 
c) NR / several hours 
Smith 66 / 
USA 
1 ♂, age 17 New Psychiatric admission, 
confusion, bizarre behaviour 
Psychosis with catatonic features , 
mild hypotension 
Self-report / SC (plus screened 
positive cannabis) 
Oral lorazepam, electro 
convulsive therapy / NR 
Takematsu 
40 / USA 
1: ♂, age 33 minor right hemiparesis, 
dysarthria, aphasia 
HR 100, BP 163/63, RR 16, Head 
CT scan: acute infarction left 
insular cortex 
GC-MS / XLR-11 NR / 3 days 
Thomas 103 / 
USA 
1: ♂, age 20 Agitation, confusion, suicidal 
ideation, self-inflicted trauma 
HR 108, RR 30,WBC 18.7k, BGC 
232, creatinine kinase 313   
Self-report “K2” Negative urine 
drug screen, alcohol zero  
Lorazepam, morphine / <2 days 
Thornton 104 
/ USA 
1: ♂, age 26 Abdominal & back pain, emesis,  HR 54, BP 151/40, RR 16, WBC 14 
k/µL creatinine 30 mg/dL 
LC-TOFMS / SC (XLR-11, UR-
144) 
NR / 6 days 
Tofighi 105 /  1: ♂, age 48 GTC seizures HR 136, BP 161/92, RR 20, GCS 6, 
creatinine kinase 2649 U/L. Became 
hyperthermic HR 186-214, BP 
59/43, required 100 Joule shock 
Self-report K2 / Negative urine 
drug screen, alcohol zero 
BZD, IV fluids, respiratory 
support/ 5 days 
Tung 106 / 
China 
1: ♂, age 36 (History of psychotic disorder) 
agitation, required restraints, 
profuse sweating 
HR 95, BP 150/90 Self-report / “K2” Restrained, midazolam IM / >10 
days 
Ukaigwe 57 / 1: ♂, age 38 Nausea, vomiting, severe HR 89, BP 115/73, RR 16, WBC 14 Self-report / “K2” IV fluids, Ondansetron / > 72 




USA abdominal pain (compulsion for 
hot showers) 
k/µL, serum electrolytes low (e.g. K 
3.4 mmol/L), creatinine 4.78 mg/dL  
hours 
Van der 
Veer 67 / 
USA 
3: ♂, age 20-
30 
All - psychotic symptoms  
a) (history of PTSD), aggression 
and suicidality,  
b) (history brief psychotic 
episodes) aggression, paranoia & 
delusions,  
c) (no psychiatric history) 
Capgras delusion & suicidality  
(Symptoms persisted – required > 2 
weeks hospitalization) 
Self-report / “Spice” “Spike 99” a) risperidone / > 2 weeks 
b) haloperidol / > 2 weeks 
c) haloperidol / > 2 weeks 
Vearrier 107 / 
USA 
1: ♀, age 17 Agitated and intoxicated HR 120, BP 135/85, hypokalaemia 
(2.9 mmol/L) 
Self-report / SC (“JWH-018”) Lorazepam 2 mg IV / NR 
Young 108 / 
USA 
1: ♂, age 17 Chest pain, dyspnoea, light-
headed 
HR 140, BP 136/78: 11 hours 
subsequently bradycardia HR 48, 
BP 121/59 




1: ♂, age 20 Withdrawal (craving, sweating, 
nightmares, nausea, tremor) 
HR 125, BP 180/90 (day 4) Self-report / “Spice” Zociplone 3.75-7.5 mg, 
promethazine 25mg, clonidine 
0.175 mg, pramipexole 0.175-
0.35 mg (off label)/ 21 days 
ADHD  = attention deficit hyperactivity disorder: BGC = blood glucose concentration: BP = blood pressure: BZD = benzodiazepines: CKMB = creatine kinase myocardial band: 
CSF = cerebrospinal fluid: EEG = electroencephalogram: DAMA = discharged against medical advice:  GC-MS Gas chromatography mass spectrometry: GCS = Glasgow coma 
score: GTC = Generalized tonic-clonic: HR = heart rate: IM = intramuscular: IV intravenous: K = Potassium: LC-ESI-T-MS = Liquid chromatography-electrospray ionization-
tandem mass spectrometry: LC-TOFMS = liquid chromatography, time-of-flight mass spectrometry: LC-QTOFMS = liquid chromatography, quadruple time-of-flight mass 
spectrometry: LC-T-MS = liquid chromatography-tandem mass spectrometry: MRI = magnetic resonance imaging: NA = not applicable: NR = not reported: PCO = partial pressure 
of carbon dioxide: RR = respiration rate: TLC = thin layer chromatography: WBC =  white blood cell count 








Online Supplementary Data 
Online Supplementary Data 1 
Search syntax - Ovid Medline  
Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE (R) 
<1996 to October 10, 2014 
1     synthetic cannabis.mp. (11) 
2     synthetic cannabinoid.mp. (558) 
3     synthetic cannabinoids.mp. (457) 
4     1 or 2 or 3 (899) 
5     emergency department.mp. or Emergency Service, Hospital/ (57833) 
6     Poison Control Centers/ or Poisoning/ or poison centre.mp. (7808) 
7     Substance-Related Disorders/ (46684) 
8     Drug Overdose/ (6311) 
9     5 or 6 or 7 or 8 (115670) 
10   4 and 9 (93) 
 
  




Online Supplementary Data 2 
Studies excluded after inspection of full text (n=31) 
 
Study  Reason for exclusion 
Bebarta 1 Abstract subsequently published - included 2  
Bottei 3 Abstract subsequently published – included 4 
Chan 5 Main substance benzofuran (SC mentioned at low concentration) 
Corkery 6 Review – did not identify types of adverse event 
Every-Palmer 7 Forensic psychiatry unit interviews 
Forrester 8 Patterns of use 
Forrester 9 Combined synthetic cannabinoid and synthetic cathinone use 
Forrester 10 Comparison of synthetic cannabinoid and MDMA use 
Forrester 11 Patterns of use 
Gunderson 12  Primary care / research study – description of use  
Hermanns-Clausen 13 Report of synthetic cannabinoid events but frequency not specified. 
Hunt 14 Not synthetic cannabinoids 
Iwanicki 15 Synthetic cannabinoid events not separated from other drug adverse events 
Jerry 16 Review – did not identify new adverse events 
Khullar 17 Not synthetic cannabinoids 
Kithinji 18  Reported patterns of use and exposure 
Kleinschmidt 19 405 cases that overlap with Forrester 20 (n=464)  
Lapoint 21  Abstract subsequently published – included 22 
Locatelli 23  Did not separate outcomes by drug type. 
Lonati 24  Includes cases reported by elsewhere 25 
Lonati 26  Did not separate outcomes by drug type. 
Maxwell 27 Review – did not identify types of adverse event  
McGuiness 2012 28 University health clinic 
McKeever 29 Abstract subsequently published – included  30 
Murphy 31 Included as CDC in Table 132 
Musshoff 33 From police data 
Pierre 34 Review – did not identify new adverse events 
Plumb 35 Sub set of Plumb 2012 36 
Rodgman 37 Insufficient data to extract (psychiatric cases) 
Tuv 38 Review – did not identify new adverse events 
Yeakel 39 From police data 
 
MDMA = methylenedioxymethamphetamine  
 




Online Supplementary Data 3  




n: sex, age 
Effects Signs & symptoms Analysis / compounds  Treatment / length of stay 
Case Series (> 10 cases) 
Bulbena-Cabre 40 
/ USA 
50: (typically  
♂, 18-25) 
Psychiatric ED – agitation, disordered 
thoughts aggression 
 Self-report SC Stabilization / NR 
Cookman a 41 / 
USA 
60: 80% ♂, 
mean age 22 
NR Tachycardia 50%, altered mental 
state 42%, agitation 33% emesis 
30% 
Self-report SC IV fluid 38%, 
benzodiazepines 15% anti 
emetics 8% / NR 
Fernandez a,b 42 / 
USA 
328: 75%, ♂ Lethargy 18%, agitation 18%, 
vomiting 17%, hallucinations 11%, 
Tachycardia 38%, hypertension 
11% 
Self-report SC NR / NR 
Hermanns-
Clausen 43 / 
Germany 
13: 92% ♂, 
median 17.5 
years 
Thoracic pain, hallucinations, 




LC-T-MS / JWH-018, -081, 
122,-250 
NR / NR 
Hermanns-
Clausen 44 / 
Germany 
35: 91% ♂, 
median age 
17.5 
Emesis 66%, somnolence 57%, 
agitation 17%, seizures 6%, aspiration 
n=1 
Tachycardia 74%, hypokalaemia 
40%, hypoxemia n=1 
LC-ESI-T-MS / JWH-018, -081, 
122, -203, -210, AM-2201, 
RCS-4 
NR / Most symptoms ceased 
within hours 
Hermanns-
Clausen 45 / 
Germany 
21: 86% ♂, 
age 13-30 
Emesis 52%, somnolence 52%, 
hyperglycaemia 43%, syncope 19%, 
dyspnoea 14%, seizures n=2 
Tachycardia 57%, hypokalaemia 
19%, elevated CK/ CK-MB 
LC-ESI-T-MS / JWH-018, -019, 
-081, 122, -200, -210, -310, 
MAM-122, 2201 RCS-4,  UR-
144 
NR / NR 
Hill a 46/ UK 53: 74% ♂, 
age 13-52 
Death n=1 agitation 19%, confusion 
19%, collapse 19%, dizziness 15% 
Low GCS/ drowsiness 23%, 
tachycardia 21% 
Self-report /  SC “Black 
mamba” 53% 
NR / NR 
Ide 47 / Japan 20: 80% ♂, 
median  age 
24.9 
Disturbance of consciousness 50%, 
hallucinations 25%, seizure n=1 
Tachycardia 50%, hypertension 
30%, tachypnea 20%, 
rhabdomyolysis n=1 
GC-MS / JWH -122, 203, -210, 
AM-694, 2001 
NR / NR 
Iwanicki 15/USA 76: 72% ♂, 
age 23-35 
Altered mental state 68%, agitation 
42%, seizures 14% 
Median HR 100, elevated 
creatinine 34%, hyperthermia 
12%, intubation required 9% 
Spectrophotometry / ADB-
PINACA 
42%  benzodiazepines, 14% 
antipsychotics, 3% ketamine / 
NR 
Locatelli a 25 / 17: (sex not Agitation 71%, confusion 47%, Tachycardia 77% Self-report + 11 laboratory Symptomatic care: 






mydriasis 41%, hallucinations 29%, 
coma n=2, seizure n=2.  
analysis / JWH-018, -022, -250 benzodiazepines / 1 day 
Lonati a 48 / Italy 32: (age & sex 
not reported) 
Agitation 50%, confusion 41%, 
mydriasis 38%, hallucinations 19%, 
coma n=4, seizure n=2 
Tachycardia 66% Self-report + 19 laboratory 
tested / JWH-018, -073, -122,  -
250 
Typically just symptomatic 
care / discharge usually 24-36 
hours 
Obafemi  49 / 
USA 
11: 45% ♂, 
age 20-57 
Memory impairment  91%, light-
headedness,  
HR > 100 18%, BP 140/90 36%,  Analysis method NR / AM2201 NR / <10 hours 




Lethargy 28%, anxiety, 25%, emesis 
21%, confusion, 16%, chest pain 13%, 
seizures 15%, hallucinations 9% 
(Of 46 with data) tachycardia 
75%, hypokalaemia 7%: n=1 for 
pneumomediastinium, atrial 
fibrillation, rhabdomyolysis 
Self-report / SC “Spice” Naloxone, BZD, potassium, 
oxygen, antiarrhythmic meds, 
alkalinization of urine, IV 
fluids /NR  
Rosenbaum a 50 / 
USA 
78: 79% ♂, 
age 12-46 
Agitation 47%, emesis / nausea 18%, 
hallucinations 10%, suicide n=1 
Median HR 122 LC-T-MS / JWH-018, -073,-081 NR / NR 
Westerbergh a 51/ 
Sweden 
214:78% ♂, 
96% < 25 
years 
Drowsiness 36%, muscular symptoms  
26%, emesis 12% 
Tachycardia 51%, hypertension 
13%, all cases mild or moderate 
severity 
NR / CRA13, JWH-018, -015, -
081, -210, -250 
NR / NR 




n: sex, age 
Effects Signs & symptoms Analysis / compounds Treatment / length of stay 
Banerji a 52 / USA 9: 100% ♂, 
median age 19 
Anticholinergic toxidrome 44%, 
agitation 44%, tremor 44%, confusion 
33%,  
Tachycardia 67%, hypertension 
22% 
Self-report / SC Symptomatic & supportive 
care: benzodiazepines n=3 / 
NR 
Besli 53 / Turkey 5: 80% ♂, age 
12-17 
3 unconscious, 2 euphoric / confused, 5 
vomiting 
Sinusal tachycardia,  NR / SC NR / NR 
Brickman 54 / 
Germany 
1: ♂, age 17 Nausea, vomiting, respiratory 
insufficiency 
NR MS: JWH-210 Intubation, ventilation / NR 
Butler 55 / USA 1: ♂, age 46 Seizures HR 140, BP 177/119, RR 10 Family report SC “Blackjack 
wild” 
Midazolam 4 mg, diazepam 
10 mg, rocuronium 100 mg, 
etomidate 20 mg, intubation / 
1 day  
Canning 56 / USA 1: ♂, age 18 Nausea, persistent vomiting, tremor, 
blurred vision 
HR 93, BP 120/65, RR 18 GC-MS + LC-T-MS / JWH-018 NR / NR 




Gerona 57 / USA 2: (age & sex 
not reported)  
Nausea, vomiting, altered mental state Tachycardia LC-TOFMS / JWH-007, -015, -
018, -073, -122, -210-398. 
NR / NR 
Grossenbacher 58 
/France 
1: ♂, age 34 Dizziness HR 100, BP 120/70  Self-report SC NR / NR 
Gunja 59 / 
Australia 
1: ♂, age 29 Chest pain, agitation HR 110, BP 170/95, RR 20, other 
tests normal ranges 
NMR-MS / 5-fluoro-AKB48 IV saline, IV midazolam 4mg 
+ 1mg, diazepam 5 mg 
Korya 60 / USA 1: ♀, age 28 Garbled speech, left side paralysis MRI: multiple embolic stokes 
right middle cerebral artery  
Self-report / “K2” NR / NR 
Locatelli 61 / Italy 1: ♂, age 20 Chest pain, dyspnoea Tachycardia 150, BP 160/80BGC 
160 mg/dL,  
Self-report / “synthecaine”, GC-
MS / SC MAM-2201, cocaine, 
benzoylecgonine 
IV fluids, 10 mg diazepam / 
12 hours 
Loschner 62 / 
USA 
1: ♂, age 19 Respiratory failure, unresponsive GSC 8 (Diffuse alveolar 
haemorrhage) 
Self-report  /“Spice”  (Urine  
test BZD and cannabinoids) 
Mechanical ventilation, 
methylprednisolone / >2 days 
McCain 63 /  USA 6: (age & sex 
not reported) 
Confusion 66%, agitation 50%, 
hallucinations 33%, emesis 33% 
Tachycardia 100% hypokalaemia 
100% 
Lab test / JWH-018, -073 BZD, anti-emetics, 
potassium, IV fluids / all < 1 
day 
McKeever 30 / 
USA 
1: ♂, age 16 Sub-sternal chest pain, dyspnoea, 
nausea, vomiting 
HR 82, BP 127/57, RR 22, peak 
troponin 8.29 ng/mL, peak 
CKMB 33.9 ng/mL.  Sub-
endocardial MI. 
Self-report / “K2” Nitro-glycerine, aspirin 
morphine / >4days 
Morris 64 / USA 1: ♂, age 20 Uncontrolled movements, spasms, 
altered mental state 
(post-operative care unit 
withdrawal symptoms) HR 120-
130 
Self-report / “Spice”   IV ativan, midazolam, 
fentanyl 
Moti 65 / USA 1: ♂, age 17 Seizure, confusion NR Self-report / “K2” NR / NR 
Remane 66 / 
Germany  
1: ♂, age 25 Dead on arrival  congestion and oedema - lung, 
brain: congestion - heart, liver, 
spleen, and kidneys 
LC-T-MS / JWH-018, -081, -
122, -210, -250 
NA / NA 
Rosenbaum 67 
/USA 
1: ♀, age 16 Agitation, seizures, vomiting Tachycardia Self-report / “Spice” Supportive care / NR 
Seifert 68 / USA 1: ♂, age 18 Seizure, acute kidney failure Serum creatinine 1.8 mg/dL, 
rhabdomyolysis (CK peak 2789) 
GC-MS / XLR-11, 4-OH JWH-
018, 5-OH JWH-018, Carboxy 
UR-144, 5-OH UR-144 
Keppra / > 6 days 
Smith 69 /  USA 1: ♀, age 24 Extreme agitation HR 140, BP 127/58, RR 30, CPK 
peak 68744, AST/ALT peak 
Self-report / injected SC BZD, supportive care /  3 




572/154 days then psychiatric care 
Streich 70 / USA 1: ♂, age 49 Asytolic cardiac arrest, died post 
admission 
ECG ST elevation in VL, V2, V3 
depression in II, III, VF and V4 





vasopressor support / 3 days 
Werner 71 / USA 1: ♂, age 26 Severe sub-sternal chest pain  HR 100, BP 124/87, RR 23. 
Troponin 16.3,  
Self-report / “K2” Standard acute coronary care / 
NR 
Yen 72 / USA 1: ♀, age 22 Left-sided weakness slurred speech, 
cerebrovascular accident  
(Non-contrast head CT, MRI, CT 
angiogram) 
Self-report / SC “K2” Hyperosmolar therapy 
mannitol / NR 
 
AST/ALT = aspartate transaminase–alanine transaminase ratio: BGC = blood glucose concentration: BP = blood pressure: CK creatine kinase: CKMB = creatine kinase myocardial 
band: CPK creatine phosphokinase: EEG = electroencephalogram: GC-MS Gas chromatography mass spectrometry: GCS = Glasgow coma score: HR = heart rate: LC-QTOFMS = 
liquid chromatography, quadruple time-of-flight mass spectrometry: LC-T-MS = liquid chromatography-tandem mass spectrometry: LC-ESI-T-MS = liquid chromatography-
electrospray ionization-tandem mass spectrometry : MI = myocardial infarction: NMR = Nuclear magnetic resonance: RR = respiration rate:  
a Poison Centre data are received from various sources but are evaluated by the poison centre staff who are trained nurses, pharmacists, or physicians. 
b Overlapping cases with Forrester 20 
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